Skip to content

Efficacy of prolonged intravenous lidocaine for postoperative pain in patients undergoing laparoscopic hysterectomy: a double-blind, randomized, placebo-controlled trial

Efficacy of prolonged intravenous lidocaine for postoperative pain in patients undergoing laparoscopic hysterectomy: a double-blind, randomized, placebo-controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097618
Enrollment
Unknown
Registered
2025-02-21
Start date
2025-02-21
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients undergoing laparoscopic hysterectomy:

Interventions

Lidocaine Group: Intervention Measures for the Lidocaine Group **1. Treatment Period**: From the initiation of anesthesia induction to 24 hours after the end of surgery. **(1) Anesthesia Protocol**:

Sponsors

Dongguan People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1)Age: 18-65 years old; 2)American Society of Anesthesiologists (ASA) physical status classification I-III; 3)Patients scheduled to undergo elective laparoscopic hysterectomy under general anesthesia; 4)Participants fully understand the purpose and significance of this trial, voluntarily agree to participate in this clinical trial, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1) Body weight less than 40 kg or greater than 100 kg; 2) Arrhythmia or systolic heart failure: second- or third-degree atrioventricular block, EF < 50%; 3) Severe liver dysfunction: AST, ALT, or bilirubin levels exceeding 2.5 times the upper limit of normal; 4) Severe renal dysfunction: creatinine clearance rate less than 60 ml/min; 5) Presence of metastatic disease in other organs; 6) Allergy to any of the trial medications; 7) Long-term use of opioid medications; 8) Inability to understand the Numeric Rating Scale (NRS) for pain assessment; 9) History of asthma or preoperative findings suggesting the possibility of asthma;

Design outcomes

Primary

MeasureTime frame
The incidence of moderate to severe movement-evoked pain within 24 hours postoperatively.;

Secondary

MeasureTime frame
The incidence of moderate to severe movement-evoked pain within 48 hours postoperatively.;The incidence of moderate to severe pain at rest within 24 hours and 48 hours postoperatively.;The cumulative opioid consumption within 24 hours and 48 hours postoperatively.;The time to recovery of gastrointestinal function (i.e., the time of the patient's first postoperative bowel movement or flatus).;The incidence of PONV within 48 hours postoperatively (including any nausea or vomiting occurring within the first 48 hours after surgery).;The incidence of postoperative pulmonary complications during the hospital stay.;Length of hospital stay (defined as the period from the end of surgery to discharge).;Patient satisfaction score.;Pain relief score;

Countries

China

Contacts

Public ContactHaihui Xie

Dongguan People's Hospital

xhh900@163.com+86 137 9058 8393

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026